

No.: 16600

Client No.:

Re No.: 16051-10US

**OGILVY  
RENAULT**

LLP/SENCRL, s.r.l.

**Facsimile****RECEIVED  
CENTRAL FAX CENTER****MAY 02 2007****Confidentiality Message**

This communication sent by facsimile is confidential, may be privileged and is intended for the exclusive use of the addressee. Any other person is strictly prohibited from disclosing, distributing or reproducing it. If the addressee cannot be reached or is unknown to you, please destroy this message and all copies. Thank you.

Number of pages including this cover sheet: 9

Date: May 2, 2007

From: Christian Cawthorn / Demian Barbas  
Our File No. 16051-10US CC/DBB/jrl

Telephone: (514) 847-4256 / 4867

Direct Fax: (514) 288-8389

E-Mail: ccawthorn@ogilvyrenault.com  
dbarbas@ogilvyrenault.com

To	Company - City	Fax
Commissioner of Patents	U.S. Patent & Trademark Office	1-571-273-8300

**Response to Office Action**  
**Due May 5, 2007**

Applicants: Andrew VAILLANT et al.

Serial Number: 10/661,355

Filing date: September 12, 2003

For: METHOD FOR IDENTIFYING ANTIVIRAL OLIGONUCLEOTIDES

Art Unit: 1648

Examiner: Sharon L. HURT

Barristers & Solicitors,  
Patent Agents & Trade-mark AgentsSuite 1600  
1981 McGill College Avenue  
Montréal, Québec H3A 2Y3  
CanadaTelephone (514) 847-4747  
Fax (514) 288-8389

ogilvyrenault.com

File No. 16051-10US CC/DBB/jrl

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

RECEIVED  
CENTRAL FAX CENTER  
MAY 02 2007

Applicants: Andrew VAILLANT et al.  
Serial Number: 10/661,355  
Filing date: September 12, 2003  
For: METHOD FOR IDENTIFYING ANTIVIRAL OLIGONUCLEOTIDES  
Art Unit: 1648  
Examiner: Sharon L. HURT  
Agent: Cawthorn, Christian (514) 847-4256

**RESPONSE TO OFFICE ACTION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia  
22313-1450

Sir:

In response to the Office Action dated February 5, 2007, in connection with the above-identified patent application, please consider the following amendment and remarks.

**AMENDMENTS TO THE SPECIFICATION**

Amendments to the Specification begin on page 2 of this paper.

**AMENDMENTS TO THE CLAIMS**

Amendments to the claims are reflected in the listing of claims which begins on page 3 of this paper.

**REMARKS**

Remarks begin on page 7 of this paper.